Ins in cancer therapy and the role with the non-target HER3. Br J Cancer 2007, 97(four):453?57.Qiu and Xu Biomarker Research 2013, 1:32 http://biomarkerres.org/content/1/1/Page 7 of16. Lian L, Ning W, Jin L: Novel targeted agents for gastric cancer. J Hematol Oncol 2012, 5:31. 17. Toikkanen S, Helin H, Isola J, Joensuu H: Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 1992, 10(7):1044?048. 18. Seshadri R, Horsfall DJ, Firgaira F, McCaul K, Setlur V, Chalmers AH, Yeo R, Ingram D, Dawkins H, Hahnel R: The relative prognostic significance of total cathepsin D and HER-2/neu oncogene amplification in breast cancer. The South Australian Breast Cancer Group. Int J Cancer 1994, 56(1):61?5. 19. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification on the Her-2/neu oncogene. Science 1987, 235(4785):177?82. 20. Jain S, Filipe MI, Gullick WJ, Linehan J, Morris RW: c-erbB-2 proto-oncogene expression and its relationship to survival in gastric carcinoma: an immunohistochemical study on archival material. Int J Cancer 1991, 48(5):668?71. 21. G ez-Martin C, Garralda E, Echarri MJ, Ballesteros A, Arcediano A, Rodr uez-Peralto JL, Hidalgo M, L ez-R s F: HER2/neu testing for anti-HER2-based therapies in sufferers with unresectable and/or metastatic gastric cancer. J Clin Pathol 2012, 65(8):751?57. 22. Sheng WQ, Huang D, Ying JM, Lu N, Wu HM, Liu YH, Liu JP, Bu H, Zhou XY, Du X: HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance. Ann Oncol 2013, 24(9):2360?364. 23. J gensen JT, Hersom M: HER2 as a prognostic marker in gastric cancer a systematic evaluation of data from the literature. J Cancer 2012, 3:137?44. 24. Pazo Cid RA, Ant A: Sophisticated HER2-positive gastric cancer: existing and future targeted therapies. Crit Rev Oncol Hematol 2013, 85(three):350?62. 25. Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA, Fumoleau P, Gianni L: Phase II trial of pertuzumab and trastuzumab in sufferers with human epidermal development aspect receptor 2-positive metastatic breast cancer that progressed in the course of prior trastuzumab therapy.Lenalidomide-5-Br supplier J Clin Oncol 2010, 28(7):1138?144.1196157-42-2 Data Sheet 26.PMID:33715956 Cort J, Fumoleau P, Bianchi GV, Petrella TM, Gelmon K, Pivot X, Verma S, Albanell J, Conte P, Lluch A, et al: Pertuzumab monotherapy soon after trastuzumab-based therapy and subsequent reintroduction of trastuzumab: activity and tolerability in sufferers with sophisticated human epidermal growth issue receptor 2-positive breast cancer. J Clin Oncol 2012, 30(14):1594?600. 27. Tabernero J, Hoff PM, Shen L, Ohtsu A, Yu R, Eng-Wong J, Kang YK: Pertuzumab (P) with trastuzumab (T) and chemotherapy (CTX) in individuals (pts) with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer: An international phase III study (JACOB) [abstract]. J Clin Oncol 2013(suppl 31):TPS4150. http://asco.org/. 28. LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX: Trastuzumab emtansine: a exceptional antibody-drug conjugate in improvement for human epidermal development issue receptor 2-positive cancer. Clin Cancer Res 2011, 17(20):6437?447. 29. Kim JG: Molecular targeted therapy for advanced gastric cancer. Korean J Intern Med 2013, 28(2):149?55. 30. Bang Y: A randomized, open-label, phase III study of lapatinib in combination with weekly pacl.
